These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34282406)

  • 1. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.
    Olender SA; Walunas TL; Martinez E; Perez KK; Castagna A; Wang S; Kurbegov D; Goyal P; Ripamonti D; Balani B; De Rosa FG; De Wit S; Kim SW; Diaz G; Bruno R; Mullane KM; Lye DC; Gottlieb RL; Haubrich RH; Chokkalingam AP; Wu G; Diaz-Cuervo H; Brainard DM; Lee IH; Hu H; Lin L; Osinusi AO; Bernardino JI; Boffito M
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab278. PubMed ID: 34282406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
    Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
    Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.
    Fusco D; Malenica I; Günthard HF; Gupta SK; Kurbegov D; Balani B; Olender S; Aberg JA; Telep LE; Tian Y; Blair C; Wu G; Haubrich RH; Wang CY; Chokkalingam AP; Osinusi AO; Wendtner CM; Gottlieb RL
    Clin Infect Dis; 2024 Nov; 79(5):1182-1189. PubMed ID: 38920297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
    Chavalertsakul K; Sutherasan Y; Petnak T; Thammavaranucupt K; Kirdlarp S; Boonsarngsuk V; Sungkanuparph S
    Int J Gen Med; 2024; 17():2163-2175. PubMed ID: 38770366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen.
    Mozaffari E; Chandak A; Chima-Melton C; Kalil AC; Jiang H; Lee E; Der-Torossian C; Thrun M; Berry M; Haubrich R; Gottlieb RL
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae202. PubMed ID: 38894848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
    Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
    Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
    Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
    Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
    Sellers J; Chang J; Jones J; Hintze TD
    Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir for the Treatment of COVID-19: A Narrative Review.
    Godwin PO; Polsonetti B; Caron MF; Oppelt TF
    Infect Dis Ther; 2024 Jan; 13(1):1-19. PubMed ID: 38193988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis.
    Santenna C; Vidyasagar K; Amarneni KC; Ghanta SN; Sadasivam B; Pathan S; Padmavathi R
    Ther Adv Drug Saf; 2021; 12():20420986211042517. PubMed ID: 34594487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.